Rusan Pharma has launched APOSAN -Apomorphine Hydrochloride (HCl), in India after approval from the DCG(I). The drug APOSAN is used for the treatment of motor fluctuations (ON-OFF) in patients with Parkinson’s Disease (PD) which are not sufficiently controlled by oral anti-Parkinson’s medication currently available in India.
The drug APOSAN will be available in the form of injections, pen and continuous infusion pumps.
The drug will cost a daily dose (between 30 – 60 mg), in India will range between ₹ 475 to ₹ 950 per day as compared to Apomorphine Pens in the UK ranging between ₹ 2,250 to ₹ 4,500 per day.
Company Profile : Rusan Pharma Ltd